Nine Continents Pharmaceutical (603456.SH) subsidiary Medication Technology passed the on-site inspection by the American FDA.

Wisdom Financial News App News, Jiuzhou Pharmaceutical (603456.SH) issued an announcement that its subsidiary, Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd. ("Pharmaceutical Technology"), underwent an on-site inspection for current Good Manufacturing Practice (cGMP) by the U.S. Food and Drug Administration (FDA) from March 17, 2025 to March 21, 2025. The inspection scope covered six major systems including quality systems, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, Pharmaceutical Technology received the Establishment Inspection Report (EIR) issued by the U.S. FDA, indicating that Pharmaceutical Technology has passed this cGMP on-site inspection.